A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2015
At a glance
- Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 17 Jun 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 18 Apr 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 18 Feb 2014 Planned End Date changed from 1 May 2015 to 1 Apr 2014 as reported by ClinicalTrials.gov record.